Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Brivaracetam Replacement for Oral Brivaracetam in Japanese Patients
NCT03685630Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in focal seizures, sponsored by UCB. Primary endpoints: Adverse Events, Subject withdrawal due to Adverse Events and 1 more. Started Jan 2019; status: completed.
02
Drugs
brivaracetam
03
Conditions
focal seizures
Beyond the preview
Go deeper on NCT03685630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685630.